POZEN Inc. (POZEN), is a pharmaceutical company focused on developing products, which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain, and pain related conditions. The Company has developed Treximet (formerly known as Trexima) in collaboration with GlaxoSmithKline (GSK). Treximet is the brand name for the product combining sumatriptan 85 milligram, formulated with RT Technology and naproxen sodium 500 milligram in a single tablet designed for the acute treatment of migraine. On April 15, 2008, the United States Food and Drug Administration (FDA) approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet incorporates the Company’s MT 400 technology, which refers to its combinations of a triptan (5-HT1B/1D agonist) and a non-steroidal, anti-inflammatory drug (NSAID).